United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
HOUSTON, Nov. 04, 2016 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, November 10, 2016 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2016, and to provide a business overview.
To access the live conference call, please call (844) 260-6671 (domestic) or (508) 915-0912 (international) at least five minutes prior to the start time, and refer to conference ID 12089547. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information: Investors Will O’Connor Stern Investor Relations 212-362-1200 [email protected] Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
